AstraZeneca secured a US regulatory win for its breast cancer therapy Etcamah on September 4, with the FDA clearing the drug under an accelerated pathway for patients whose tumors carry an ESR1 resistance mutation. The decision follows Phase 3 data showing a 56 percent lower risk of progression or death, and the company sees the drug as a potential $5 billion annual revenue driver.
The US regulator cleared AstraZeneca's once-daily oral SERD camizestrant (Etcamah) for ESR1-mutated advanced breast cancer on September 4, following Phase 3 data showing the therapy cut the risk of disease progression or death by 56 percent versus standard hormone therapy.
AstraZeneca projects Etcamah could reach more than $5 billion in annual sales, while consensus forecasts put the drug at roughly $2.3 billion by 2032, according to market data cited by Bloomberg.
The approval covers use in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative breast cancer that has spread. The drug is a next-generation selective estrogen receptor degrader, meaning it both blocks and breaks down the estrogen receptor that drives these tumors. In the SERENA-6 Phase 3 trial, switching to Etcamah cut the risk of disease progression or death by 56 percent versus staying on the original hormone therapy. The FDA also cleared Guardant Health's Guardant360 CDx blood test as a companion diagnostic to identify eligible patients.
The clearance came despite an FDA advisory committee vote against the drug in April 2026, which questioned the trial's switch-on-mutation design rather than the drug itself. Etcamah is already approved in the EU, Japan, the UAE and Saudi Arabia.
The ESR1 mutation is present in fewer than 5 percent of patients at diagnosis but appears in nearly 40 percent after the cancer progresses on hormone therapy. Etcamah is designed to be switched in as soon as the mutation is detected in the blood, before the cancer visibly worsens on scans. Patients must undergo an FDA-approved diagnostic test confirming the presence of the mutation before receiving the therapy.
AstraZeneca has reported that Etcamah can delay disease progression by more than six months in eligible patients. The therapy functions as a hormone therapy by blocking estrogen from activating cancer cells, thereby slowing their growth.
The approval strengthens AstraZeneca's position in the competitive oncology market, where the company competes with Pfizer, Eli Lilly and Roche in the breast cancer space. Under CEO Pascal Soriot, AstraZeneca has expanded its portfolio of cancer medicines and launched several successful therapies.
The US clearance gives AstraZeneca a new revenue stream in a large oncology market. Investors will watch the drug's commercial launch trajectory and whether physician adoption matches the company's $5 billion peak-sales ambition, with the first full quarter of US sales data as the next key data point.
This article is for informational purposes only and does not constitute investment advice.
